 |
인쇄하기
취소
|
Government Oks sale of locally-produced hemophilia A treatment
Korea’s health authorities gave the green light to Green Cross Corp. on August 30 to sell Greengene-F injection, an albumin-free, B-domain deleted (BDD) recombinant human coagulation factor VIIIB domain VIII.
It is the third medicine to treat hemophilia A following those developed by companies in the United States.
Greengene-F, an updated version of Greengene approved in 2008, is characte...
It is the third medicine to treat hemophilia A following those developed by companies in the United States.
Greengene-F, an updated version of Greengene approved in 2008, is characte...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.